Razvoj programske aplikacije za upravljanje varijantnim modelom lamelne spojke

Tema ovog rada je izrada programske aplikacije za upravljanje varijantnim modelom lamelne spojke. U tu svrhu razvijena je samostalna exe. aplikacija primjenom C#.NET programskog jezika. Tako razvijena aplikacije integrirana je sa SolidWorks CAD programskom paketom preko programskog aplikacijskog sučelja (API). Ulazni podaci potrebni za proračun unose se preko grafičkog korisničkog sučelja (GUI). Rezultati proračuna prosljeđuju se programksom paketu SolidWorks, koji učitava promjene modela lamelne spojke. Korištenjem razvijene aplikacije smanjuje se vrijeme potrebno za projektiranje i modeliranje, pa su i ukupni troškovi projektiranja također smanjeni

Wer ist Nebukadnezzar im Buche Daniel?

Gemäss seinem Titel »Wer ist Nebukadnezzar im Buche Daniel?« versucht dieser Artikel, anhand einiger Texte des letzten babylonischen Königs Nabonid auf diese Frage zu antworten. Zunächst werden die Episoden aus dem Leben des »Propheten Daniel« in Dan 1-6 einzeln analysiert. Dadurch wird die ursprüngliche Eigenständigkeit einerjeden davon ausgemacht und das darin gebotene Bild »Nebukadnezzars« als historisch ünzutrefflich, übertrieben und manchmal unlogisch klargestellt. Es folgt eine Darstellung der wichtigsten Begebenheiten aus dem Leben des letzten babylonischen Königs Nabonid und die Übersicht all seiner heutzutage bekannten Inschriften bzw. der Texte über ihn, und zwar sowohl jener, die ihm ablehnend gegenüberstehen, als auch jener, die ihm positiv gesinnt sind. Um zu zeigen, dass die Beschreibung »Nebukadnezzars« in Dan 1-6 eherauf Nabonid als auf Nebukadnezzar II zutrifft, werden exemplarisch zwei akkadische Texte zum ersten Mal in kroatischer Sprache übersetzt und entsprechend erklärt. Es sind die Königsinschrift Nabonids über die Weihe seiner Tochter zur entu-Priesterin (A. T. CLAY, Miscellaneous Inscriptions in the Yale Babylonian Collection [Yale Oriental Series. Babylonian Texts, Vol. 1], London 1915, Pl. XXXIII, Nr. 45) und das sog. »Strophengedicht« über Nabonid (S. SMITH, Babylonian Historical Texts, London 1924, Pl. V-X). In den Anmerkungen werden zu diesem letztgenannten Text einige nette Ergänzungs-bzw. Lesungsvorschläge unterbreitet

Ispitivanje statusa željeza u dobrovoljnih davatelja krvi u Republici Hrvatskoj [Investigation of iron status in Croatian blood donors]

Introduction: With each donation of whole blood, healthy blood donor loses 200 – 250 mg of iron. This loss is compensated by the mobilization of stored iron. Several studies showed that blood donors may be at risk of iron deficiency/depletion and the development of anemia. This risk is particularly pronounced in female donors of childbearing age and frequent blood donors. Therefore, implementation of numerous measures are considered in order to prevent iron deficiency and improve the safety of blood donors. Aim: The aim of this study was to evaluate the iron status of voluntary blood donors in Croatia, primarily by measuring ferritin level in donors with different donation freqency, to assess the diagnostic value of RBC parameters, as well as combined cell index (CCI) in detecting reduced iron stores, to evaluate the blood donor safety in relation to the iron stores using current selection criteria and to consider the implementation of measures to prevent iron deficiency, particularly the introduction of ferritin testing in blood donors. Methods: The study involved 1,084 male and 792 female whole blood donors, accepted for blood donation. In addition to the short questionnaire about general data and lifestyle, two additional samples were collected: one for the determination of complete blood count (CBC) and one for the determination of ferritin, serum iron, UIBC/TIBC. Statistical analysis was performed using the MedCalc software and Excel 2016. Results: In male donors, linear drop of serum ferritin was demonstrated with increasing frequency of blood donations:from the median of 129 μg/L in the control group to 43 μg/L in those with 7 – 8 donations in two years. In control group of female donors, the median value of ferritin was 33 μg/L, while in test groups the median ferritin was within a narrow range between 22 μg/L and 29 μg/L, and in correlation with the menstrual status. Depleted iron stores (ferritin ˂12 μg/L) were found in males with the frequency of 0% in the control group and 1.95% in those with 1 – 8 donations in two years. Depleted iron stores were found in 6.7% females of the control group and in 17.2% of female donors with 1 – 6 donations in two years. Combined Cell Index (CCI) showed satisfactory diagnostic value in the assessment of depleted iron stores in both sexes. Conclusion: In addition to more intense education of blood donors on the importance of iron and its loss during the blood donation, we propose the implementation of quantitative method for haemoglobin determination, along with the gradual introduction of ferritin test

Mogranj od bjelokosti - jedina »relikvija« iz Salomonova hrama?

An die Beschreibung eines Granatapfels aus Elfenbein, der im Israel-Museum in Jerusalem ausgestellt ist, schließt sich die Darstellung der Bedeutung dieser Frucht in der biblischen und jüdischen Tradition, sowie im konkreten Leben und in der Kunst des Hl. Landes im Altertum an

Heparin-Induced Thrombocytopenia (HIT)

Heparin-induced thrombocytopenia (HIT I) is a severe, life-threatening, and immunological drug reaction. According to the clinical-laboratory characteristics, there are two types of HIT: type I (HIT I) and type II (HIT II). HIT I is the result of non-immunologic, direct interaction of heparin with the platelet surface. Contrary, HIT II is immunologically induced (antibody-mediated) and life-threatening side effect of heparin therapy, often associated with thromboembolic complications. All patients receiving heparin are exposed to the development of anti-heparin antibodies, irrespective of the heparin dosage, type, and method of administration. HIT most commonly develops in intensive care patients, dialyzed patients, and cardiosurgical and orthopedic patients. It commonly develops after 5–10 days of heparin therapy. Platelet count decreases by more than 50% from the baseline and ranges from 20 × 109/L to 100 × 109/L. In HIT II, thromboembolic complications usually include deep-vein thrombosis and pulmonary embolism, but they also include arterial occlusion of the extremities, myocardial infarction, stroke, and necrosis and organ damage. Clinical assessment of the HIT probability using 4T´s score system, systematic monitoring of platelet number in heparin-receiving patients, and specific laboratory diagnosis of anti-heparin antibodies substantially contribute to the final confirmation of the diagnosis, enable timely administration of direct non-heparin thrombin antagonists, and reduce mortality from thromboembolic complications

International forum. an investigation of iron status in blood donors

No abstract availabl

INDICATIONS AND CONTRAINDICATIONS FOR PLATELET TRANSFUSIONS IN PATIENTS WITH THROMBOCYTOPENIA

Više od 40 godina trombocitne transfuzije potporno su liječenje koje spašava život hematološkim bolesnicima s poremećajem hematopoeze, u aplaziji koštane srži nakon kemoterapije, kirurškim bolesnicima i u drugim bolestima s poremećajima broja i funkcije trombocita. U Europi se na godinu transfundira više od 2,9 mil. doza trombocitnih pripravaka, a u Republici Hrvatskoj oko 57.000. Poseban izazov u liječenju jesu bolesnici u jedinicama intenzivnog liječenja s trombocitopenijom i udruženom koagulopatijom. Prije odluke o trombocitnoj transfuziji u ovih bolesnika važno je procijeniti potencijalnu opasnost od trombogenog učinka transfuzije u odnosu na korist u sprječavanju krvarenja. Primjena trombocitnih transfuzija, uključujući indikacije i kontraindikacije, dozu i transfuzijski prag znatno se razlikuju u kliničkoj praksi i još uvijek postoje brojna neriješena pitanja. Pri tome pridržavanje preporuka za transfuzijsko liječenje može umnogome pridonijeti kvaliteti, sigurnosti i ostvarenju osnovnih ciljeva u liječenju trombocitnim krvnim pripravcima.For more than 40 years now, platelet transfusion has provided life-saving supportive therapy to hematological patients with impaired hematopoiesis, bone marrow aplasia induced by chemotherapy, surgical patients and patients with a variety of disorders of platelet count and function. More than 2.9 million platelet components are transfused each year in Europe and 57000 in Croatia. Patients with thrombocytopenia and coagulopathy treated at intensive care units pose special challenges. It is essential to assess the potential risk of thrombogenic side effects over the benefit of stopping and preventing bleeding before platelet transfusion in these patients. Although transfusion practices including indications and contraindications for transfusion, the dose of platelets transfused and ‘transfusion trigger’ are variable and in some cases the best practices are not fully known, greater harmonization of policies might promote the quality, safety and optimal use of platelet products

Research of the Influence of Air Transportation on Blood Sample Quality

In air freight industry, blood samples are classified as time and temperature sensitive biologically produced pharmaceuticals. To determine the level of influence that the handling processes and air transportation have on blood sample quality, a research has been conducted through transportation of whole blood samples on two European scheduled routes. Two shipping models were defined: the standard one without defined transportation temperature regime and the controlled one, where transportation is conducted under appropriate temperature regime. The blood samples were packed and transported respecting all relevant national and international regulations. The analysis was conducted and the results compared to control sample kept in the laboratory. Significant changes were identified on all components analyzed after crosschecking with the control sample. KEY WORDS: regulatory issues, blood sample quality, shipping model, packaging instruction, temperature profile